Printer Friendly

United States District Court upholds validity of Lilly's Evista patents through 2014.

The United States District Court for the Southern District of Indiana upheld Eli Lilly and Company's (Indianapolis, IN) method-of-use patents on Evista (raloxifene HCl tablets). In the case of Eli Lilly and Company v. Teva Pharmaceuticals Industries Ltd., the court ruled in favor of Lilly on all accounts for these method-of-use patents, including the patent doctrines of obviousness, enablement, and inequitable conduct. These patents provide protection for Evista through March of 2014.

"We are pleased with the court's rulings on Evista's method-of-use patents. We have always been very confident that these patents are valid and enforceable and today's court ruling sends a clear message on the strength of those patents," said Robert A. Armitage, senior vice president and general counsel for Lilly. "Protection of intellectual property rights is extremely important to the biopharmaceutical industry and the physicians and patients we serve, as these rights help support the development of the next generation of innovative medicines to treat unmet medical needs."

In addition, the Court held Lilly's Evista particle-size patents invalid. The company is reviewing this aspect of the ruling to determine whether or not to appeal.

Evista is a medicine indicated for the treatment and prevention of osteoporosis in postmenopausal women; and the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and the reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.

Lilly is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations.

Eli Lilly and Company

+1-317-276-5795

www.lilly.com
COPYRIGHT 2009 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Aug 1, 2009
Words:268
Previous Article:Oxygen Biotherapeutics, Inc. files patent application for emergency heart attack treatment device.
Next Article:Brinks Hofer Gilson & Lione wins patent appeal for Cook Incorporated Federal Circuit holds that Cook's Endovascular graft devices do not infringe.
Topics:


Related Articles
Zyprexa patent upheld.
Legal victory for Astra; US court upholds firm's drug patent.
Judge blocked generic Evista launch, says Lilly.
United States District Court rules against Lilly regarding Gemzar Patent Lilly plans appeal to defend Gemzar's intellectual property.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters